Regeneron and Inovio to conduct Phase Ib/IIa combination trial to treat GBM

Regeneron Pharmaceuticals has entered a clinical study agreement with Inovio Pharmaceuticals to conduct its Phase Ib/IIa clinical trial of REGN2810 in combination with INO-5401 and INO-9012 to treat patients with newly diagnosed glioblastoma multifor …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news